Fund Holdings — Krensavage Asset Management, LLC

Total Portfolio Value:
$255.7K
Total Bought:
$36.1K
Total Sold:
$60.3K
Net Transaction:
-$24.2K
Securities
▲▼
SharesValue
Q4 2025
▲▼
Q1 2026
▲▼
Change
▲▼
Q4 2025
▲▼
Q1 2026
▲▼
Weight (%)
▲▼
Change
▲▼
United Therapeutics Corporation(UTHR)91,28284,282-7,000$44.5K$50.0K19.55%+$5.5K
Enanta Pharmaceuticals, Inc.(ENTA)2,766,3902,866,138+99,748$43.6K$36.2K14.16%-$7.4K
Jazz Pharmaceuticals plc(JAZZ)167,816167,8160$28.5K$31.7K12.41%+$3.2K
BioMarin Pharmaceutical Inc.(BMRN)524,786524,7860$31.2K$29.6K11.59%-$1.5K
Exelixis, Inc.(EXEL)493,526415,693-77,833$21.6K$17.8K6.97%-$3.8K
SanofiADR(SNY)323,946323,9460$15.7K$15.6K6.10%-$90
Supernus Pharmaceuticals, Inc.(SUPN)313,499280,681-32,818$15.6K$14.5K5.67%-$1.1K
Indivior Pharmaceuticals, Inc.(INDV)0339,532+339,532$0$10.3K4.05%+$10.3K
Ultragenyx Pharmaceutical Inc.(RARE)149,634390,879+241,245$3.4K$8.2K3.20%+$4.7K
Vanda Pharmaceuticals Inc.(VNDA)1,180,3881,180,3880$10.4K$8.2K3.19%-$2.3K
Embecta Corp.(EMBC)0735,340+735,340$0$6.5K2.54%+$6.5K
GSK plcADR(GSK)96,72996,7290$4.7K$5.3K2.09%+$594
BioNTech SEADR(BNTX)99,52359,523-40,000$9.5K$5.3K2.07%-$4.2K
Alkermes plc(ALKS)107,822107,8220$3.0K$3.8K1.49%+$796
Biogen Inc.(BIIB)10,00020,000+10,000$1.8K$3.7K1.43%+$1.9K
Regeneron Pharmaceuticals, Inc.(REGN)4,0004,0000$3.1K$3.1K1.21%+$4
Ardelyx Inc0500,000+500,000$0$3.0K1.17%+$3.0K
InMode Ltd.(INMD)0120,942+120,942$0$1.7K0.65%+$1.7K
Evolus, Inc.(EOLS)100,000157,985+57,985$665$6490.25%-$16
Abbott Laboratories05,000+5,000$0$5130.20%+$513
Avadel Pharmaceuticals855,8600-855,860$18.4K$0—-$18.4K
Cardinal Health, Inc.(CAH)73,7450-73,745$15.2K$0—-$15.2K
Indivior Plc339,5320-339,532$12.2K$0—-$12.2K
Page 1 of 1
Krensavage Asset Management, LLC — 13F Holdings — Q1 2026 | TickerTrail